Skip to main content
Nanologica logo

Nanologica — Investor Relations & Filings

Ticker · NICA ISIN · SE0005454873 LEI · 54930017L41C7P87LP22 ST Manufacturing
Open in API
Filings indexed 181 across all filing types
Latest filing 2023-10-17 Regulatory Filings
Country SE Sweden
Listing ST NICA

About Nanologica

https://nanologica.com/

Nanologica is a life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. The company specializes in nanoporous silica particles for preparative chromatography, a critical step in drug production. Its core product, NLAB Saga®, is a spherical, porous silica media engineered for the large-scale purification of peptide drugs, such as insulin and GLP-1 analogues used to treat diabetes and obesity. The product's high mechanical and chemical stability provides effective purification and a long lifetime, which increases productivity and reduces costs for pharmaceutical manufacturers. Nanologica's mission is to lower the manufacturing costs of these drugs, thereby increasing patient access to life-saving treatments. The company is also developing a broader portfolio of purification media.

Recent filings

Filing Released Lang Actions
Nanologica levererar silika till insulintillverkare för utvärdering i produktion
Regulatory Filings Classification · 99% confidence The document is a press release written in Swedish announcing that Nanologica is delivering silica to an insulin manufacturer for evaluation in full-scale production. It includes quotes from the CEO, company background, and contact information for IR. Crucially, the final paragraph states: "Denna information är sådan information som Nanologica AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is information that Nanologica AB (publ) is obliged to disclose under the EU Market Abuse Regulation). This strongly indicates a mandatory regulatory disclosure. Since it is not a full financial report (10-K, IR), a specific corporate action (DIV, CAP, SHA), or a management/board change (MANG, DIRS), and it is a general announcement required by regulation, it best fits the general regulatory announcement category, which is RNS (Regulatory Filings). The document length is short (3342 chars) and it announces news rather than being the detailed report itself.
2023-10-17 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT Q2 2023' (Interim Report Q2 2023) for Nanologica AB. It contains comprehensive financial statements, including income statements, cash flow data, balance sheet items, and detailed management commentary on business performance, market outlook, and operational milestones for the second quarter and the first half of the year. It is a substantive financial report rather than a mere announcement or certification. Q2 2023
2023-07-07 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'INTERIM REPORT Q2 2023' for Nanologica AB. It contains comprehensive financial statements, key performance indicators, management commentary (CEO comment), and detailed business area analysis for the second quarter and half-year period. It is a substantive financial report rather than a short announcement or certification, fitting the definition of an Interim/Quarterly Report. Q2 2023
2023-07-07 English
Förändringar i Nanologicas koncernstruktur och ledningsgrupp för fullt fokus på kromatografi
Board/Management Information Classification · 98% confidence The document announces significant changes within Nanologica AB, specifically focusing on a strategic shift to concentrate on chromatography and the subsequent adjustment of the senior management team (ledningsgruppen). It explicitly states that the CSO and VP Drug Development are leaving the company. This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management. Although it discusses business strategy, the core announcement is personnel and structural change at the executive level.
2023-05-08 Swedish
Changes in Nanologica’s Group Structure and Management Team for Full Focus on Chromatography
Board/Management Information Classification · 98% confidence The document explicitly announces changes in the company's management team (CSO Gary Pitcairn and VP Drug Development Ulf Ericsson leaving) and a strategic shift in business focus (prioritizing Chromatography over Drug Development). This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management. Although it discusses strategy, the primary focus and headline are on the management team adaptation. The document is short and appears to be a press release announcing the change, not a comprehensive report.
2023-05-08 English
Bulletin from the AGM Nanologica AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Bulletin from the AGM Nanologica AB (publ)" and details resolutions adopted during the Annual General Meeting (AGM), such as the adoption of financial statements, discharge of directors, election of the board, approval of fees, and resolutions regarding share issues and incentive programs. This content directly corresponds to the purpose of an AGM meeting summary or report. Therefore, the classification code is AGM-R.
2023-05-04 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.